121 related articles for article (PubMed ID: 12944920)
21. Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity.
Bywater MJ; Burkhart DL; Straube J; Sabò A; Pendino V; Hudson JE; Quaife-Ryan GA; Porrello ER; Rae J; Parton RG; Kress TR; Amati B; Littlewood TD; Evan GI; Wilson CH
Nat Commun; 2020 Apr; 11(1):1827. PubMed ID: 32286286
[TBL] [Abstract][Full Text] [Related]
22. P-TEFb as A Promising Therapeutic Target.
Fujinaga K
Molecules; 2020 Feb; 25(4):. PubMed ID: 32075058
[TBL] [Abstract][Full Text] [Related]
23. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
[TBL] [Abstract][Full Text] [Related]
24. Chemical modulation of transcription factors.
Wiedemann B; Weisner J; Rauh D
Medchemcomm; 2018 Aug; 9(8):1249-1272. PubMed ID: 30151079
[TBL] [Abstract][Full Text] [Related]
25. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
26. Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors.
Moreno N; Holsten T; Mertins J; Zhogbi A; Johann P; Kool M; Meisterernst M; Kerl K
Oncotarget; 2017 Oct; 8(49):84986-84995. PubMed ID: 29156698
[TBL] [Abstract][Full Text] [Related]
27. Low expression of
Ruan P; Tao Z; Tan A
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29026005
[TBL] [Abstract][Full Text] [Related]
28. Nascent RNA sequencing reveals a dynamic global transcriptional response at genes and enhancers to the natural medicinal compound celastrol.
Dukler N; Booth GT; Huang YF; Tippens N; Waters CT; Danko CG; Lis JT; Siepel A
Genome Res; 2017 Nov; 27(11):1816-1829. PubMed ID: 29025894
[TBL] [Abstract][Full Text] [Related]
29. MYC-Master Regulator of the Cancer Epigenome and Transcriptome.
Poole CJ; van Riggelen J
Genes (Basel); 2017 May; 8(5):. PubMed ID: 28505071
[TBL] [Abstract][Full Text] [Related]
30. Menin enhances c-Myc-mediated transcription to promote cancer progression.
Wu G; Yuan M; Shen S; Ma X; Fang J; Zhu L; Sun L; Liu Z; He X; Huang D; Li T; Li C; Wu J; Hu X; Li Z; Song L; Qu K; Zhang H; Gao P
Nat Commun; 2017 May; 8():15278. PubMed ID: 28474697
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
32. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms and Developmental Roles of Promoter-proximal Pausing of RNA Polymerase II.
Robinson C; Lowe M; Schwartz A; Kikyo N
J Stem Cell Res Ther; 2016 Mar; 6(3):. PubMed ID: 27158559
[TBL] [Abstract][Full Text] [Related]
34. Myc coordinates transcription and translation to enhance transformation and suppress invasiveness.
Elkon R; Loayza-Puch F; Korkmaz G; Lopes R; van Breugel PC; Bleijerveld OB; Altelaar AF; Wolf E; Lorenzin F; Eilers M; Agami R
EMBO Rep; 2015 Dec; 16(12):1723-36. PubMed ID: 26538417
[TBL] [Abstract][Full Text] [Related]
35. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.
Cai Q; Medeiros LJ; Xu X; Young KH
Oncotarget; 2015 Nov; 6(36):38591-616. PubMed ID: 26416427
[TBL] [Abstract][Full Text] [Related]
36. MYC: connecting selective transcriptional control to global RNA production.
Kress TR; Sabò A; Amati B
Nat Rev Cancer; 2015 Oct; 15(10):593-607. PubMed ID: 26383138
[TBL] [Abstract][Full Text] [Related]
37. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
[TBL] [Abstract][Full Text] [Related]
38. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.
Lu H; Xue Y; Yu GK; Arias C; Lin J; Fong S; Faure M; Weisburd B; Ji X; Mercier A; Sutton J; Luo K; Gao Z; Zhou Q
Elife; 2015 Jun; 4():e06535. PubMed ID: 26083714
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
40. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.
Gregory GP; Hogg SJ; Kats LM; Vidacs E; Baker AJ; Gilan O; Lefebure M; Martin BP; Dawson MA; Johnstone RW; Shortt J
Leukemia; 2015 Jun; 29(6):1437-41. PubMed ID: 25578475
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
